Prostate cancer preferentially metastasizes to bone and the mortality from prostate cancer is 70% once bone metastases are present. In addition, prostate cancer-induced bone metastases are associated with significant complications including severe pain, skeletal fractures, spinal cord compression and bone marrow suppression. Most doctors structure their treatment protocols against bone metastases by treating the cancer [...]
Watson Pharmaceuticals, Inc. (WPI), announced that the U.S. Food and Drug Administration (FDA) has approved MIXJECT, which is a new delivery system for TRELSTAR (triptorelin pamoate for injectable suspension). The delivery system includes some new features, a smaller 21-gauge needle that should improve comfort and a shield covering the needle both before and after drug [...]
Are you taking Fosamax to help combat osteoporosis? Many of us take Fosamax as one of the most common side effects of a hormone blockade (ADT) is loss of bone density. ADT causes osteoporosis, or a decrease in bone density, which diminishes bone strength. A decrease in your bone density increases your chance to suffer [...]
April 14 in the Journal of Clinical Oncology reported that Eric M. Horwitz, M.D., from Fox Chase Cancer Center in Philadelphia, and colleagues treated 1,554 prostate cancer patients with goserelin and flutamide (ADT) before and during radiation therapy. The men were then randomly assigned to receive no further ADT or 24 additional months of ADT. [...]
At the European Association of Urology’s 23rd Annual Congress there was an abstract presented (Abstract 186) that concluded that three-dimensional external beam radiation (EBRT) with 6 months of androgen deprivation therapy (ADT) for the treatment of patients with locally advanced prostate cancer shows significantly shorter patient survival than the same treatment followed by 3 years [...]